Therefore, using a monoclonal antibody to inhibit PD-1/PD-L1 co-inhibitory pathways might be an effective therapeutic approach to reverse immune suppression and to activate a cancer-specific immune response in cervical cancer patients. Here, CD274 is linked to cervical cancer.